Claritas Pharmaceuticals (CLAZF) Ratios
Claritas Pharmaceuticals Ratios
CLAZF's free cash flow for Q3 2021 was $-281.00K. For the 2021 fiscal year, CLAZF's free cash flow was increased by $0.00 and operating cash flow was $-281.00K. See a summary of the company’s cash flow.
| Ratios | Dec 20 | Sep 20 | Mar 19 | Dec 17 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 0.14 | 0.03 | 0.10 | 0.95 |
| Quick Ratio | 0.14 | 0.03 | 0.10 | 0.95 |
| Cash Ratio | 0.00 | 0.01 | 0.03 | 0.92 |
| Solvency Ratio | 0.45 | -0.41 | 0.36 | -0.41 |
| Operating Cash Flow Ratio | -0.04 | -1.13 | -0.62 | -1.39 |
| Short-Term Operating Cash Flow Coverage | -0.33 | -17.86 | -19.71 | 0.00 |
| Net Current Asset Value | $ -7.96M | $ -28.54M | $ -49.10M | $ -73.11M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.09 | 0.03 | 0.00 | 0.04 |
| Debt-to-Equity Ratio | 0.61 | -0.21 | 0.03 | -0.25 |
| Debt-to-Capital Ratio | 0.38 | -0.27 | 0.02 | -0.33 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.12 | 0.00 | -0.33 |
| Financial Leverage Ratio | 6.93 | -7.35 | 6.11 | -5.61 |
| Debt Service Coverage Ratio | 1.82 | -21.16 | 45.70 | -0.85 |
| Interest Coverage Ratio | -14.56 | -45.22 | -72.56 | -0.90 |
| Debt to Market Cap | 69.31 | 1.76 | 0.83 | 2.50 |
| Interest Debt Per Share | 0.04 | 0.04 | 0.03 | 3.05 |
| Net Debt to EBITDA | -0.33 | -0.04 | 0.00 | 0.05 |
| Profitability Margins | ||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | -624.63% | 82.11% | 101.45% | 100.00% |
| EBT Per EBIT | 20.57% | 273.35% | -61.57% | 219.76% |
| Return on Assets (ROA) | 40.31% | -83.99% | 11.63% | -48.81% |
| Return on Equity (ROE) | 279.36% | 617.17% | 71.03% | 273.90% |
| Return on Capital Employed (ROCE) | -98.76% | -48.48% | -21.44% | -23.66% |
| Return on Invested Capital (ROIC) | 482.39% | -39.08% | -21.34% | -22.29% |
| Return on Tangible Assets | 429.15% | -13175.16% | 928.38% | -838.72% |
| Earnings Yield | 31546.21% | -5081.90% | 2327.09% | -2782.33% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -0.01 | -0.29 | -0.39 | -0.90 |
| Free Cash Flow Per Share | -0.01 | -0.29 | -0.39 | -0.90 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -0.33 | -8.81 | -19.71 | -1.94 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -2315.39% | -1553.18% | -1626.78% | -485.60% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | 0.00 | -0.02 | 0.04 | -0.04 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.01 | -0.12 | 0.03 | -0.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.04 | -0.06 | -0.06 | -0.21 |
| Price-to-Operating Cash Flow Ratio | -0.04 | -0.06 | -0.06 | -0.21 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.00 | -0.00 | 0.00 |
| Enterprise Value Multiple | -0.33 | -0.07 | 0.02 | -0.02 |
| Enterprise Value | 933.35K | 1.12M | 317.01K | 327.19K |
| EV to EBITDA | -0.33 | -0.07 | 0.02 | -0.02 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.02 | -0.17 | -0.07 | -0.06 |
| EV to Operating Cash Flow | -3.02 | -0.17 | -0.07 | -0.06 |
| Tangible Book Value Per Share | -0.30 | -1.27 | -3.92 | -11.78 |
| Shareholders’ Equity Per Share | 0.06 | -0.15 | 0.78 | -1.87 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | 7.25 | 0.18 | -0.01 | 0.06 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | 0.16 | -0.95 | 0.55 | -5.13 |
| Tax Burden | -6.25 | 0.82 | 1.01 | 1.00 |
| Interest Burden | -3.66 | 0.99 | 1.03 | 2.06 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | -0.07 | 0.31 | -0.70 | 0.17 |
Currency in USD
